Tfr2 Essential for Acute Hepcidin Induction in Tfr1-Deficient Mouse Hepatocytes

Molecular Sensing and the Regulation of Systemic Iron Homeostasis

Hepcidin serves as the master hormonal regulator of systemic iron by binding to the exporter ferroportin (a protein that moves iron out of cells), which triggers its degradation and limits iron entry into the plasma [1]. In clinical practice, disruptions in this homeostatic loop are most frequently encountered in hereditary hemochromatosis, where deficient hepcidin signaling leads to progressive tissue iron overload and subsequent organ damage [2, 3]. While the liver is the primary site of hepcidin synthesis, the specific mechanisms by which hepatocytes sense circulating iron levels remain a subject of intense investigation [4, 5, 6]. Current models suggest a complex interplay between various membrane proteins, including transferrin receptors and the hemochromatosis protein (HFE), to fine-tune the body's iron balance [2, 5]. A recent study using targeted genetic ablation (the precise laboratory removal of specific genes to observe functional loss) provides a granular view of how transferrin receptor 2 and HFE act cooperatively to induce hepcidin during acute iron challenges [7]. For clinicians managing iron-loading disorders, these findings clarify that while these receptors are dispensable for basic hepatocellular iron supply, they are essential for the rapid hormonal adjustments required to prevent systemic iron spikes [7, 5].

Dissecting the Role of Transferrin Receptors in Iron Uptake

To clarify the specific contributions of transferrin receptors to hepatic iron metabolism, researchers generated a specialized mouse model featuring hepatocyte-specific ablation (the targeted genetic removal of genes strictly within liver cells) of both transferrin receptor 1 (Tfr1) and transferrin receptor 2 (Tfr2). These TfrcAlb-Cre;Tfr2Alb-Cre mice allowed the team to observe how the loss of these receptors impacts iron homeostasis without affecting other organ systems. The study focused on the functional distinction between Tfr1, which is traditionally associated with cellular iron acquisition, and its homolog Tfr2, which is thought to serve primarily as a sensor for circulating iron levels.

The experimental data revealed that in hepatocytes, transferrin receptor 1 plays a limited role in iron acquisition, despite being the primary mediator of iron uptake in most other cell types. To test the efficiency of iron internalization, the researchers exposed primary hepatocytes to fluorescent holo-transferrin (AF647-Tf), a form of transferrin bound to iron that can be tracked via imaging. The results showed that only Tfr1-expressing primary hepatocytes from Tfrcfl/fl;Tfr2fl/fl and Tfr2Alb-Cre mice internalized the fluorescent holo-transferrin, whereas cells lacking Tfr1 failed to do so. This finding indicates that transferrin receptor 2 or other alternative receptors do not significantly contribute to transferrin-bound iron uptake in these cells. Consequently, the study concludes that transferrin receptors are dispensable for hepatocellular iron supply. For practicing physicians, this suggests that the liver utilizes different, non-transferrin-dependent pathways to maintain its own cellular iron levels, ensuring hepatic survival even when primary receptor pathways are disrupted.

Phenotypic Consequences of Dual Receptor Deficiency

The researchers observed that the TfrcAlb-Cre;Tfr2Alb-Cre mice, which lack both Tfr1 and Tfr2 in their hepatocytes, are viable and develop systemic iron overload. This systemic accumulation of iron mirrors a primary clinical feature of hereditary hemochromatosis, a condition characterized by excessive iron absorption and tissue deposition. While Tfr1 is typically associated with iron uptake, its regulatory role in the liver is more complex. In hepatocytes, transferrin receptor 1 negatively regulates signaling to the iron hormone hepcidin (Hamp) through its interaction with the hemochromatosis protein Hfe. Under normal physiological conditions, this interaction sequesters Hfe, preventing it from stimulating hepcidin production. When Tfr1 is absent, Hfe is released from this inhibitory complex, creating a state the authors describe as liberated Hfe.

The phenotypic expression of iron overload in these double-knockout mice differs significantly from models lacking only Tfr2. Specifically, the TfrcAlb-Cre;Tfr2Alb-Cre mice show milder hepatic iron accumulation compared to Tfr2Alb-Cre mice. This relative reduction in liver iron storage is accompanied by distinct hormonal profiles that have direct implications for understanding iron sensing. The TfrcAlb-Cre;Tfr2Alb-Cre mice show relatively higher residual hepcidin expression than Tfr2Alb-Cre mice, a finding that the researchers attribute to the presence of liberated Hfe. Because Tfr1 is no longer present to bind and inhibit Hfe, the protein is free to promote hepcidin transcription, even in the absence of Tfr2. This mechanism suggests that while Tfr2 is a positive regulator of hepcidin, the loss of the inhibitory Tfr1 can partially compensate by allowing Hfe to drive residual hormone expression, thereby modulating the severity of the iron overload phenotype.

Hepcidin Response Under Dietary Iron Restriction

To understand how the liver adapts to iron deficiency, the researchers placed the mice under dietary iron restriction. In this low-iron environment, the suppression of hepcidin (Hamp) mRNA and the resulting depletion of hepatic iron stores were comparable between TfrcAlb-Cre;Tfr2Alb-Cre mice and Tfr2Alb-Cre mice. This finding indicates that when Tfr2 is absent, the liver's ability to downregulate hepcidin in response to low systemic iron remains consistent, regardless of whether Tfr1 is also missing. For the clinician, this suggests that the regulatory pathways governing the body's response to iron deficiency may bypass certain receptor interactions that are otherwise critical during iron surplus.

The study further elucidated a compensatory mechanism involving the hemochromatosis protein Hfe, a known regulator of hepcidin. In the Tfr2Alb-Cre mice, dietary iron restriction led to a compensatory upregulation of transferrin receptor 1, a response that likely serves to sequester Hfe and prevent it from stimulating hepcidin production. This sequestration ensures that hepcidin levels remain low so that the body can maximize iron absorption during a shortage. In contrast, the TfrcAlb-Cre mice, which are transferrin receptor 1 deficient but still express transferrin receptor 2, displayed relatively elevated Hamp mRNA levels. Because these mice lack the Tfr1 needed to bind and inhibit Hfe, the protein remains available to drive hepcidin expression, even when the diet is iron-poor. These results highlight that Tfr1 acts as a molecular brake on Hfe, and its absence can disrupt the appropriate hormonal response to iron deficiency, potentially complicating the clinical management of concurrent anemia and iron-loading states.

The Necessity of Tfr2 in Acute Iron Sensing

The study identifies transferrin receptor 2 (Tfr2) as a specialized iron sensor and a direct positive regulator of hepcidin expression, the hormone responsible for maintaining systemic iron balance. While Tfr1 primarily manages cellular iron uptake and sequesters the hemochromatosis protein Hfe, Tfr2 is essential for signaling the liver to produce hepcidin when iron levels rise. To evaluate this sensing mechanism, the researchers subjected mice to an acute dietary iron challenge, simulating a rapid influx of the mineral. They found that Hamp mRNA induction occurred only in the liver of Tfr2-expressing TfrcAlb-Cre mice, which lack Tfr1 but retain Tfr2. In contrast, the double-knockout TfrcAlb-Cre;Tfr2Alb-Cre mice failed to mount a hepcidin response, demonstrating that Tfr2 is the indispensable trigger for this acute hormonal adjustment.

The failure of the double-knockout mice to respond to iron was traced to a breakdown in intracellular signaling. The researchers observed that Smad1,5,9 phosphorylation (a signaling cascade that moves the iron signal from the cell surface to the nucleus to activate hepcidin expression) occurred only in the liver of Tfr2-expressing TfrcAlb-Cre mice following the acute iron challenge. Furthermore, the findings clarify the role of the hemochromatosis protein Hfe in this process. Although Hfe is released from its inhibitory bond with Tfr1 in these models, the data show that liberated Hfe requires Tfr2 to become functionally active in inducing hepcidin. Without Tfr2 as a partner, Hfe cannot effectively stimulate the Smad signaling pathway during rapid iron fluctuations.

These results establish a nuanced hierarchy in iron regulation that has direct implications for understanding hereditary hemochromatosis and other iron-loading disorders. The researchers concluded that Tfr2 and Hfe exhibit nonredundant functions under chronic iron loading, meaning each protein contributes uniquely to long-term iron homeostasis. However, the two proteins must act cooperatively to induce hepcidin in response to an acute iron challenge. For the clinician, this suggests that the liver's ability to defend against sudden iron spikes is dependent on a functional unit formed by Tfr2 and Hfe, and a deficiency in either component may leave a patient vulnerable to rapid iron accumulation even if their baseline chronic iron management pathways appear partially compensated.

References

1. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science. 2004. doi:10.1126/science.1104742

2. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011. doi:10.1002/hep.24330

3. Zheng H, Yang F, Deng K, et al. Relationship between iron overload caused by abnormal hepcidin expression and liver disease: A review.. Medicine. 2023. doi:10.1097/MD.0000000000033225

4. Liu J, Sun B, Yin H, Liu S. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.. Medicine. 2016. doi:10.1097/MD.0000000000003150

5. Ikhtiar F, Jamal A, Arif A, Shahid MN, Bokhari SMSM. Hemochromatosis and Hepatic Complications: A Comprehensive Review of Molecular Mechanisms, Diagnostics, and Emerging Therapeutics.. Current molecular medicine. 2025. doi:10.2174/0115665240371495250505054101

6. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proceedings of the National Academy of Sciences. 2005. doi:10.1073/pnas.0409808102

7. Liu S, Tsyplenkova S, Charlebois E, et al. Tfr2 is necessary for acute iron-dependent hepcidin induction in mice with Tfr1-deficient hepatocytes.. Blood. 2026. doi:10.1182/blood.2025030054